CoverOne offers a Bridge program to assist eligible patients to obtain their initial prescription of TEPMETKO® (tepotinib) free of charge, if the following criteria are met.
The patient must:
Be a new patient with a prescription for TEPMETKO
Be diagnosed by their physician with the FDA approved indication of TEPMETKO.
Be insured (i.e., a commercial insurer or a federal health care program)
Have experienced a delay in a coverage determination of at least 5 business days
To determine patient eligibility for the Bridge program, please complete and submit the CoverOne TEPMETKO Enrollment Form.
NOTE: Bridge program is only applicable for TEPMETKO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
You are about to leave the CoverOne website and are being redirected to a non-CoverOne website. EMD Serono does not review nor control the content of the following website. This redirection does not constitute an endorsement by EMD Serono of the following organization or any information provided by the organization.